Kynostatin 272  (Synonyms: KNI 272; Kynostatin; NSC 651714)

Kynostatin 272 (KNI 272) is a potent HIV protease inhibitor. Kynostatin 272 inhibits the activity of the HIV protease by simulating the substrate transition state of the HIV protease, thus preventing a key step in the replication of the HIV virus. Kynostatin 272 provides an important research foundation for the development of drugs for HIV and AIDS^[1][2].

667.84

C₃₃H₄₁N₅O₆S₂

147318-81-8

O=C(N1[C@@H](CSC1)C(NC(C)(C)C)=O)[C@@H](O)[C@H](CC2=CC=CC=C2)NC([C@H](CSC)NC(COC3=C4C(C=NC=C4)=CC=C3)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kimura T, et al. Rigid backbone moiety of KNI-272, a highly selective HIV protease inhibitor: methanol, acetone and dimethylsulfoxide solvated forms of 3-[3-benzyl-2-hydroxy-9-(isoquinolin-5-yloxy)-6-methylsulfanylmethyl-5, 8-dioxo-4, 7-diazanonanoyl]-N-tert-butyl-1, 3-thiazolidine-4-carboxamide[J]. Acta Crystallographica Section B: Structural Science, 2004, 60(4): 433-437.

  [2]. Freedberg D I, et al. Flexibility and function in HIV protease: Dynamics of the HIV-1 protease bound to the asymmetric inhibitor kynostatin 272 (KNI-272)[J]. Journal of the American Chemical Society, 1998, 120(31): 7916-7923.